Skip to main content
Top
Published in: Arthritis Research & Therapy 6/2012

Open Access 01-12-2012 | Research article

Silencing of microRNA-101 prevents IL-1β-induced extracellular matrix degradation in chondrocytes

Authors: Linghui Dai, Xin Zhang, Xiaoqing Hu, Chunyan Zhou, Yingfang Ao

Published in: Arthritis Research & Therapy | Issue 6/2012

Login to get access

Abstract

Introduction

Extracellular matrix (ECM) degradation leads to malfunction of the cartilage in osteoarthritis (OA). Inflammatory cytokine interleukin-1 beta (IL-1β) functions in ECM degradation and prevents ECM synthesis by down-regulating the key transcription factor, Sox9, and consequently inhibiting ECM gene expression. Evidence reveals that microRNAs (miRNA) have been associated with OA, but little is known of their function in chondrocyte ECM degradation. This study aimed to identify possible miRNAs that mediate IL-1β-induced down-regulation of Sox9 as well as its known down-stream genes, collagen type II and aggrecan.

Methods

The miRNAs were predicted based on three classical databases. The expression levels of the predicted miRNAs were assessed in IL-1β stimulated chondrocytes by real-time PCR. A luciferase reporter was used to test the binding of the miRNAs to the 3' untranslated regions (3'UTR) of Sox9. The predicted miRNAs were transfected into chondrocytes to validate their relationship with Sox9. Functional analysis of the miRNAs on chondrocytes ECM degradation was performed at both the mRNA and protein levels after miRNA transfection and IL-1β treatment.

Results

Six miRNAs were predicted to target Sox9, and their expression in IL-1β-stimulated chondrocytes was revealed by real-time PCR. The luciferase reporter assay indicated that only miR-101 could bind to the 3'UTR of Sox9. The expression of Sox9 was likewise negatively regulated by miR-101 in rat chondrocytes. Functional analysis showed that miR-101 could aggravate chondrocyte ECM degradation, whereas miR-101 inhibition could reverse IL-1β-induced ECM degradation.

Conclusion

miR-101 participates in IL-1β-induced chondrocyte ECM degradation. Down-regulating miR-101 expression can prevent the IL-1β-induced ECM degradation in chondrocytes. miR-101 probably functions by directly targeting Sox9 mRNA.
Appendix
Available only for authorised users
Literature
2.
go back to reference Sandell LJ, Aigner T: Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res. 2001, 3: 107-113. 10.1186/ar148.PubMedCentralCrossRefPubMed Sandell LJ, Aigner T: Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res. 2001, 3: 107-113. 10.1186/ar148.PubMedCentralCrossRefPubMed
3.
go back to reference Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H: Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011, 7: 33-42. 10.1038/nrrheum.2010.196.CrossRefPubMed Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H: Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011, 7: 33-42. 10.1038/nrrheum.2010.196.CrossRefPubMed
4.
go back to reference Shinmei M, Masuda K, Kikuchi T, Shimomura Y: The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol Suppl. 1989, 18: 32-34. 10.3109/03009748909103710.CrossRefPubMed Shinmei M, Masuda K, Kikuchi T, Shimomura Y: The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol Suppl. 1989, 18: 32-34. 10.3109/03009748909103710.CrossRefPubMed
5.
go back to reference Burrage PS, Mix KS, Brinckerhoff CE: Matrix metalloproteinases: role in arthritis. Front Biosci. 2006, 11: 529-543. 10.2741/1817.CrossRefPubMed Burrage PS, Mix KS, Brinckerhoff CE: Matrix metalloproteinases: role in arthritis. Front Biosci. 2006, 11: 529-543. 10.2741/1817.CrossRefPubMed
6.
go back to reference Sylvester J, Ahmad R, Zafarullah M: Role of Sp1 transcription factor in Interleukin-1-induced ADAMTS-4 (aggrecanase-1) gene expression in human articular chondrocytes. Rheumatol Int. 2011. Sylvester J, Ahmad R, Zafarullah M: Role of Sp1 transcription factor in Interleukin-1-induced ADAMTS-4 (aggrecanase-1) gene expression in human articular chondrocytes. Rheumatol Int. 2011.
7.
go back to reference Murakami S, Lefebvre V, de Crombrugghe B: Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-alpha. J Biol Chem. 2000, 275: 3687-3692. 10.1074/jbc.275.5.3687.CrossRefPubMed Murakami S, Lefebvre V, de Crombrugghe B: Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-alpha. J Biol Chem. 2000, 275: 3687-3692. 10.1074/jbc.275.5.3687.CrossRefPubMed
8.
go back to reference Pujol JP, Chadjichristos C, Legendre F, Bauge C, Beauchef G, Andriamanalijaona R, Galera P, Boumediene K: Interleukin-1 and transforming growth factor-beta 1 as crucial factors in osteoarthritic cartilage metabolism. Connect Tissue Res. 2008, 49: 293-297. 10.1080/03008200802148355.CrossRefPubMed Pujol JP, Chadjichristos C, Legendre F, Bauge C, Beauchef G, Andriamanalijaona R, Galera P, Boumediene K: Interleukin-1 and transforming growth factor-beta 1 as crucial factors in osteoarthritic cartilage metabolism. Connect Tissue Res. 2008, 49: 293-297. 10.1080/03008200802148355.CrossRefPubMed
9.
go back to reference Sekiya I, Tsuji K, Koopman P, Watanabe H, Yamada Y, Shinomiya K, Nifuji A, Noda M: SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6. J Biol Chem. 2000, 275: 10738-10744. 10.1074/jbc.275.15.10738.CrossRefPubMed Sekiya I, Tsuji K, Koopman P, Watanabe H, Yamada Y, Shinomiya K, Nifuji A, Noda M: SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6. J Biol Chem. 2000, 275: 10738-10744. 10.1074/jbc.275.15.10738.CrossRefPubMed
10.
go back to reference Lefebvre V, Huang W, Harley VR, Goodfellow PN, de Crombrugghe B: SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol. 1997, 17: 2336-2346.PubMedCentralCrossRefPubMed Lefebvre V, Huang W, Harley VR, Goodfellow PN, de Crombrugghe B: SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol. 1997, 17: 2336-2346.PubMedCentralCrossRefPubMed
11.
go back to reference Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, Ling KW, Sham MH, Koopman P, Tam PP, Cheah KS: SOX9 directly regulates the type-II collagen gene. Nat Genet. 1997, 16: 174-178. 10.1038/ng0697-174.CrossRefPubMed Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, Ling KW, Sham MH, Koopman P, Tam PP, Cheah KS: SOX9 directly regulates the type-II collagen gene. Nat Genet. 1997, 16: 174-178. 10.1038/ng0697-174.CrossRefPubMed
12.
go back to reference Legendre F, Dudhia J, Pujol JP, Bogdanowicz P: JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem. 2003, 278: 2903-2912. 10.1074/jbc.M110773200.CrossRefPubMed Legendre F, Dudhia J, Pujol JP, Bogdanowicz P: JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem. 2003, 278: 2903-2912. 10.1074/jbc.M110773200.CrossRefPubMed
13.
go back to reference Tili E, Michaille JJ, Costinean S, Croce CM: MicroRNAs, the immune system and rheumatic disease. Nat Clin Pract Rheumatol. 2008, 4: 534-541. 10.1038/ncprheum0885.CrossRefPubMed Tili E, Michaille JJ, Costinean S, Croce CM: MicroRNAs, the immune system and rheumatic disease. Nat Clin Pract Rheumatol. 2008, 4: 534-541. 10.1038/ncprheum0885.CrossRefPubMed
14.
go back to reference O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D: Physiological and pathological roles for microRNAs in the immune system. Nat rev Immunol. 2010, 10: 111-122. 10.1038/nri2708.CrossRefPubMed O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D: Physiological and pathological roles for microRNAs in the immune system. Nat rev Immunol. 2010, 10: 111-122. 10.1038/nri2708.CrossRefPubMed
15.
go back to reference Dai R, Ahmed SA: MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res. 2011, 157: 163-179. 10.1016/j.trsl.2011.01.007.PubMedCentralCrossRefPubMed Dai R, Ahmed SA: MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res. 2011, 157: 163-179. 10.1016/j.trsl.2011.01.007.PubMedCentralCrossRefPubMed
17.
go back to reference Miyaki S, Sato T, Inoue A, Otsuki S, Ito Y, Yokoyama S, Kato Y, Takemoto F, Nakasa T, Yamashita S, Takada S, Lotz MK, Ueno-Kudo H, Asahara H: MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev. 2010, 24: 1173-1185. 10.1101/gad.1915510.PubMedCentralCrossRefPubMed Miyaki S, Sato T, Inoue A, Otsuki S, Ito Y, Yokoyama S, Kato Y, Takemoto F, Nakasa T, Yamashita S, Takada S, Lotz MK, Ueno-Kudo H, Asahara H: MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev. 2010, 24: 1173-1185. 10.1101/gad.1915510.PubMedCentralCrossRefPubMed
18.
go back to reference Tardif G, Hum D, Pelletier JP, Duval N, Martel-Pelletier J: Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. BMC Musculoskelet Disord. 2009, 10: 148-10.1186/1471-2474-10-148.PubMedCentralCrossRefPubMed Tardif G, Hum D, Pelletier JP, Duval N, Martel-Pelletier J: Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. BMC Musculoskelet Disord. 2009, 10: 148-10.1186/1471-2474-10-148.PubMedCentralCrossRefPubMed
19.
go back to reference Akhtar N, Rasheed Z, Ramamurthy S, Anbazhagan AN, Voss FR, Haqqi TM: MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes. Arthritis Rheum. 2010, 62: 1361-1371.PubMedCentralCrossRefPubMed Akhtar N, Rasheed Z, Ramamurthy S, Anbazhagan AN, Voss FR, Haqqi TM: MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes. Arthritis Rheum. 2010, 62: 1361-1371.PubMedCentralCrossRefPubMed
20.
go back to reference Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
21.
go back to reference Farndale RW, Buttle DJ, Barrett AJ: Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta. 1986, 883: 173-177. 10.1016/0304-4165(86)90306-5.CrossRefPubMed Farndale RW, Buttle DJ, Barrett AJ: Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta. 1986, 883: 173-177. 10.1016/0304-4165(86)90306-5.CrossRefPubMed
22.
go back to reference Chandrasekhar S, Esterman MA, Hoffman HA: Microdetermination of proteoglycans and glycosaminoglycans in the presence of guanidine hydrochloride. Anal Biochem. 1987, 161: 103-108. 10.1016/0003-2697(87)90658-0.CrossRefPubMed Chandrasekhar S, Esterman MA, Hoffman HA: Microdetermination of proteoglycans and glycosaminoglycans in the presence of guanidine hydrochloride. Anal Biochem. 1987, 161: 103-108. 10.1016/0003-2697(87)90658-0.CrossRefPubMed
23.
go back to reference Jeong CG, Hollister SJ: A comparison of the influence of material on in vitro cartilage tissue engineering with PCL, PGS, and POC 3D scaffold architecture seeded with chondrocytes. Biomaterials. 2010, 31: 4304-4312. 10.1016/j.biomaterials.2010.01.145.PubMedCentralCrossRefPubMed Jeong CG, Hollister SJ: A comparison of the influence of material on in vitro cartilage tissue engineering with PCL, PGS, and POC 3D scaffold architecture seeded with chondrocytes. Biomaterials. 2010, 31: 4304-4312. 10.1016/j.biomaterials.2010.01.145.PubMedCentralCrossRefPubMed
24.
go back to reference Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM: MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009, 69: 1135-1142.CrossRefPubMed Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM: MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009, 69: 1135-1142.CrossRefPubMed
28.
go back to reference Martinez-Sanchez A, Dudek KA, Murphy CL: Regulation of human chondrocyte function through direct inhibition of cartilage master regulator SOX9 by microRNA-145 (miRNA-145). J Biol Chem. 2012, 287: 916-924. 10.1074/jbc.M111.302430.PubMedCentralCrossRefPubMed Martinez-Sanchez A, Dudek KA, Murphy CL: Regulation of human chondrocyte function through direct inhibition of cartilage master regulator SOX9 by microRNA-145 (miRNA-145). J Biol Chem. 2012, 287: 916-924. 10.1074/jbc.M111.302430.PubMedCentralCrossRefPubMed
29.
go back to reference Yang B, Guo H, Zhang Y, Chen L, Ying D, Dong S: MicroRNA-145 regulates chondrogenic differentiation of mesenchymal stem cells by targeting Sox9. PLoS One. 2011, 6: e21679-10.1371/journal.pone.0021679.PubMedCentralCrossRefPubMed Yang B, Guo H, Zhang Y, Chen L, Ying D, Dong S: MicroRNA-145 regulates chondrogenic differentiation of mesenchymal stem cells by targeting Sox9. PLoS One. 2011, 6: e21679-10.1371/journal.pone.0021679.PubMedCentralCrossRefPubMed
30.
go back to reference Schnabel M, Marlovits S, Eckhoff G, Fichtel I, Gotzen L, Vecsei V, Schlegel J: Dedifferentiation-associated changes in morphology and gene expression in primary human articular chondrocytes in cell culture. Osteoarthritis Cartilage. 2002, 10: 62-70. 10.1053/joca.2001.0482.CrossRefPubMed Schnabel M, Marlovits S, Eckhoff G, Fichtel I, Gotzen L, Vecsei V, Schlegel J: Dedifferentiation-associated changes in morphology and gene expression in primary human articular chondrocytes in cell culture. Osteoarthritis Cartilage. 2002, 10: 62-70. 10.1053/joca.2001.0482.CrossRefPubMed
31.
go back to reference Schulze-Tanzil G: Activation and dedifferentiation of chondrocytes: implications in cartilage injury and repair. Ann Anat. 2009, 191: 325-338. 10.1016/j.aanat.2009.05.003.CrossRefPubMed Schulze-Tanzil G: Activation and dedifferentiation of chondrocytes: implications in cartilage injury and repair. Ann Anat. 2009, 191: 325-338. 10.1016/j.aanat.2009.05.003.CrossRefPubMed
33.
go back to reference Howell DS: Pathogenesis of osteoarthritis. Am J Med. 1986, 80: 24-28. 10.1016/0002-9343(86)90075-6.CrossRefPubMed Howell DS: Pathogenesis of osteoarthritis. Am J Med. 1986, 80: 24-28. 10.1016/0002-9343(86)90075-6.CrossRefPubMed
34.
go back to reference Hamerman D: The biology of osteoarthritis. N Engl J Med. 1989, 320: 1322-1330. 10.1056/NEJM198905183202006.CrossRefPubMed Hamerman D: The biology of osteoarthritis. N Engl J Med. 1989, 320: 1322-1330. 10.1056/NEJM198905183202006.CrossRefPubMed
35.
go back to reference Tew SR, Hardingham TE: Regulation of SOX9 mRNA in human articular chondrocytes involving p38 MAPK activation and mRNA stabilization. J Biol Chem. 2006, 281: 39471-39479. 10.1074/jbc.M604322200.CrossRefPubMed Tew SR, Hardingham TE: Regulation of SOX9 mRNA in human articular chondrocytes involving p38 MAPK activation and mRNA stabilization. J Biol Chem. 2006, 281: 39471-39479. 10.1074/jbc.M604322200.CrossRefPubMed
36.
go back to reference Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008, 322: 1695-1699. 10.1126/science.1165395.PubMedCentralCrossRefPubMed Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008, 322: 1695-1699. 10.1126/science.1165395.PubMedCentralCrossRefPubMed
37.
go back to reference Friedman JM, Jones PA, Liang G: The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. Cell Cycle. 2009, 8: 2313-2314. 10.4161/cc.8.15.9168.PubMedCentralCrossRefPubMed Friedman JM, Jones PA, Liang G: The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. Cell Cycle. 2009, 8: 2313-2314. 10.4161/cc.8.15.9168.PubMedCentralCrossRefPubMed
38.
go back to reference Yu D, Tan AH, Hu X, Athanasopoulos V, Simpson N, Silva DG, Hutloff A, Giles KM, Leedman PJ, Lam KP, Goodnow CC, Vinuesa CG: Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature. 2007, 450: 299-303. 10.1038/nature06253.CrossRefPubMed Yu D, Tan AH, Hu X, Athanasopoulos V, Simpson N, Silva DG, Hutloff A, Giles KM, Leedman PJ, Lam KP, Goodnow CC, Vinuesa CG: Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature. 2007, 450: 299-303. 10.1038/nature06253.CrossRefPubMed
Metadata
Title
Silencing of microRNA-101 prevents IL-1β-induced extracellular matrix degradation in chondrocytes
Authors
Linghui Dai
Xin Zhang
Xiaoqing Hu
Chunyan Zhou
Yingfang Ao
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 6/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4114

Other articles of this Issue 6/2012

Arthritis Research & Therapy 6/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine